Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.

Clinical genetics - 1 May 1999

Tonin P N, Mes-Masson A M, Narod S A, Ghadirian P, Provencher D

Abstract excerpt

The breast cancer susceptibility genes, BRCA1 and BRCA2, differ in their contribution to ovarian cancer. Recently, founder mutations in each of these genes were identified in Canadian breast cancer and breast ovarian cancer families of French ancestry. We have examined the prevalence of the found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Canada
Share to Founder Effect

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to France

Share to Genes, BRCA1

Share to Neoplasm Proteins

Share to Ovarian Neoplasms

Share to Transcription Factors

Source

Identifiers

PMID: 10422801
DOI: 10.1034/j.1399-0004.1999.550504.x

Genes

BRCA1
BRCA2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-10422801-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.PMID 10422801Read ↗

Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.Semantic proximity Read ↗

[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].Semantic proximity Read ↗

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.Semantic proximity Read ↗

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.Semantic proximity Read ↗

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.Semantic proximity Read ↗

The contribution of BRCA1 and BRCA2 to ovarian cancer.Semantic proximity Read ↗

The contribution of founder mutations to early-onset breast cancer in French-Canadian women.Semantic proximity Read ↗

Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.Semantic proximity Read ↗

Founder mutations in BRCA1 and BRCA2 genes.Semantic proximity Read ↗

The genetic analysis of a founder Northern American population of European descent identifies<i>FANCI</i>as a candidate familial ovarian cancer risk geneSemantic proximity Read ↗

BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.Semantic proximity Read ↗

Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.